Sarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity Investment

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has sold 9,265,312 shares of common stock of Arrowhead Pharmaceuticals, Inc. (“Arrowhead”) in a privately negotiated block trade. The Company expects to receive at least $174 million in gross proceeds from the block trade. In addition, Sarepta entered into an agreement with Arrowhead pursuant to which it will transfer 2,660,989 shares o